

Saskia Ingen-Housz-Oro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4973270/publications.pdf>

Version: 2024-02-01

166
papers

3,681
citations

159358

30
h-index

168136

53
g-index

216
all docs

216
docs citations

216
times ranked

2997
citing authors

#	ARTICLE	IF	CITATIONS
1	Response to systemic therapies in granulomatous cheilitis: Retrospective multicenter series of 61 patients. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 667-669.	0.6	3
2	Lupus erythematosus and epidermal necrolysis: a case series of 16 patients. <i>British Journal of Dermatology</i> , 2022, 186, 372-374.	1.4	3
3	Don't Judge a Book by its Cover. "Steroid Acne": an unrecognized role of <i>Malassezia</i> and <i>Demodex</i> ? <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
4	Incidence and severity of COVID-19 in patients with autoimmune blistering skin diseases: A nationwide study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 494-497.	0.6	18
5	Calcinosis cutis in epidermal necrolysis: role of caspofungin?. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	3
6	Real-life impact of immunologic tests to predict relapse after treatment cessation in patients with bullous pemphigoid: A French multicenter retrospective study. <i>Journal of the American Academy of Dermatology</i> , 2022, 86, 1293-1300.	0.6	2
7	Epidermal necrolysis: characterization of different phenotypes using an unsupervised clustering analysis. <i>British Journal of Dermatology</i> , 2022, 186, 1037-1039.	1.4	2
8	Life-threatening skin reaction with Enfortumab Vedotin: Six cases. <i>European Journal of Cancer</i> , 2022, 167, 168-171.	1.3	10
9	Severe blistering eruptions induced by immune checkpoint inhibitors: a multicentre international study of 32 cases. <i>Melanoma Research</i> , 2022, 32, 205-210.	0.6	11
10	Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase. <i>Pharmacoepidemiology and Drug Safety</i> , 2022, 31, 434-441.	0.9	2
11	High frequency of eosinophilia and viral reactivation in drug hypersensitivity in patients with severe acute respiratory syndrome coronavirus 2 infection. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
12	Axonal Guillain-Barré syndrome and toxic epidermal necrolysis: two cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
13	Bullous pemphigoid: Three main clusters defining 3 outcome profiles. <i>Journal of the American Academy of Dermatology</i> , 2022, 87, 359-365.	0.6	7
14	Cutaneous gamma delta T-cell lymphoma with indolent evolution: a series of five cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	2
15	Prevalence of T-cell antigen losses in mycosis fungoides and CD30-positive cutaneous T-cell lymphoproliferations in a series of 153 patients. <i>Pathology</i> , 2022, 54, 729-737.	0.3	7
16	Psychotherapeutic interventions for burns patients and the potential use with Stevens-Johnson syndrome and toxic epidermal necrolysis patients: A systematic integrative review. <i>PLoS ONE</i> , 2022, 17, e0270424.	1.1	2
17	Carrying out local care for epidermal necrolysis: survey of practices. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e155-e157.	1.3	2
18	Involvement of small-diameter nerve fibres in long-term chronic pain after Stevens-Johnson syndrome or toxic epidermal necrolysis. A neurophysiological assessment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e218-e221.	1.3	2

#	ARTICLE	IF	CITATIONS
19	Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry*. British Journal of Dermatology, 2021, 184, 1059-1067.	1.4	39
20	Acute generalized exanthematous pustulosis induced by enoxaparin: 2 cases. Contact Dermatitis, 2021, 84, 280-282.	0.8	4
21	Chronic pain: a long-term sequela of epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) of Dermatology and Venereology, 2021, 35, 188-194.	1.3	10
22	Locoregional nodal extension does not impair prognosis of primary cutaneous anaplastic lymphomas. British Journal of Dermatology, 2021, 184, 356-358.	1.4	1
23	Mycosis fungoïde et lymphomes T myérodermiques. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 40-47.	0.0	1
24	Essential oils as potential triggers for bullous pemphigoid? A report of two patients. European Journal of Dermatology, 2021, 31, 92-93.	0.3	2
25	Dermatose à IgA linéaires. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 118-121.	0.0	0
26	Œrythme polymorphe. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 578-578.	0.0	0
27	Prise en charge d'un exanthème maculo-papuleux. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 114-117.	0.0	1
28	Relapsing generalized bullous fixed drug eruption: A severe and avoidable cutaneous drug reaction. Three case reports. Therapie, 2021, , .	0.6	4
29	Characteristics and risk factors for poor outcome in patients with systemic vasculitis involving the gastrointestinal tract. Seminars in Arthritis and Rheumatism, 2021, 51, 436-441.	1.6	10
30	Supportive care in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: an international, multidisciplinary Delphi-based consensus. British Journal of Dermatology, 2021, 185, 616-626.	1.4	22
31	Pustulose exanthématique aiguë généralisée (PEAG). Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 177-181.	0.0	1
32	Which patients present to dermatologic emergencies? A survey on 1561 patients. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e583-e585.	1.3	1
33	Towards a better understanding of adult idiopathic epidermal necrolysis: a retrospective study of 19 cases. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1569-1576.	1.3	4
34	Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms. European Journal of Dermatology, 2021, 31, 372-380.	0.3	7
35	Nonuraemic calciphylaxis: A case series. Annales De Dermatologie Et De Venereologie, 2021, 148, 127-129.	0.5	1
36	Dermatite herpétiforme. Annales De Dermatologie Et De Vénéréologie, FMC, 2021, 1, 319-321.	0.0	0

#	ARTICLE	IF	CITATIONS
37	Intravenous immunoglobulins: an eye opener on the successful treatment of severe adult-onset paraprotein-associated xanthogranulomatosis. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1346-1348.	0.6	0
38	Lymphomatoid papulosis types D and E: a multicentre series of the French Cutaneous Lymphomas Study Group. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1441-1451.	0.6	6
39	Childhood epidermal necrolysis and erythema multiforme major: a multicentre French cohort study of 62 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 2051-2058.	1.3	7
40	Assessment of Treatment Approaches and Outcomes in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>JAMA Dermatology</i> , 2021, 157, 1182.	2.0	27
41	Lymph node and visceral progression without erythroderma or blood worsening in erythrodermic cutaneous T-cell lymphoma: nine cases. <i>British Journal of Dermatology</i> , 2021, 185, 1061-1063.	1.4	2
42	Syphilis has no age limit. <i>Age and Ageing</i> , 2021, 50, 2270-2270.	0.7	1
43	Pityriasis lichenoides: a clinical and pathological case series of 49 patients with an emphasis on follow-up. <i>Clinical and Experimental Dermatology</i> , 2021, 46, 1561-1566.	0.6	1
44	16S metagenomic assessment of the skin microbiota dynamic and possible association with the risk of infection in patients with epidermal necrolysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e914-e917.	1.3	1
45	Impact of systemic to topical steroids switch on the outcome of drug reaction with eosinophilia and systemic symptoms (DRESS): A monocenter retrospective study of 20 cases. <i>Annales De Dermatologie Et De Venereologie</i> , 2021, 148, 168-171.	0.5	8
46	International multicentre observational study to assess the efficacy and safety of a 0.5 mg kg ⁻¹ per day starting dose of oral corticosteroids to treat bullous pemphigoid. <i>British Journal of Dermatology</i> , 2021, , .	1.4	8
47	Lymphomes B cutanés primitifs indolents: lymphome B centrofolliculaire et lymphome B de la zone marginale. <i>Annales De Dermatologie Et De Venereologie, FMC</i> , 2021, 1, 589-589.	0.0	0
48	Patch tests in non-immediate cutaneous adverse drug reactions: the importance of late readings on day 4. <i>Contact Dermatitis</i> , 2021, , .	0.8	5
49	Défaillance cutanée aiguë: conséquences et principes généraux de prise en charge. <i>Annales De Dermatologie Et De Venereologie, FMC</i> , 2021, 1, 583-588.	0.0	0
50	PD1 in Scleroderma syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?. <i>European Journal of Cancer</i> , 2021, 156, S14-S15.	1.3	1
51	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021, 156, S23-S24.	1.3	1
52	Missed Diagnosis of Epilepsy-Associated Scald Burns: Two Cases Initially Diagnosed as Bullous Dermatoses. <i>Journal of Burn Care and Research</i> , 2021, 42, 569-572.	0.2	0
53	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021, 138, 790-790.	0.6	4
54	Evaluation of Thalidomide Treatment of Patients With Chronic Erythema Multiforme. <i>JAMA Dermatology</i> , 2021, 157, 1472.	2.0	5

#	ARTICLE	IF	CITATIONS
55	Trends in mortality rates for Stevens-Johnson syndrome and toxic epidermal necrolysis: experience of a single centre in France between 1997 and 2017. <i>British Journal of Dermatology</i> , 2020, 182, 247-248.	1.4	16
56	Acute exanthemas: a prospective study of 98 adult patients with an emphasis on cytokinic and metagenomic investigation. <i>British Journal of Dermatology</i> , 2020, 182, 355-363.	1.4	9
57	Cross-reactivity in beta-lactams after a non-immediate cutaneous adverse reaction: experience of a reference centre for toxic bullous diseases and severe cutaneous adverse reactions. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 787-794.	1.3	12
58	Health-related quality of life and long-term sequelae in survivors of epidermal necrolysis: an observational study of 57 patients. <i>British Journal of Dermatology</i> , 2020, 182, 916-926.	1.4	24
59	Incidence of and mortality from epidermal necrolysis (Stevens-Johnson syndrome/toxic epidermal) <i>Tj ETQq1 1 0.784314 rgBT /Over Dermatology</i> , 2020, 182, 618-624.	1.4	29
60	Individual and hospital-level factors associated with epidermal necrolysis mortality: a nationwide multilevel study, France, 2012-2016. <i>British Journal of Dermatology</i> , 2020, 182, 900-906.	1.4	13
61	Rituximab is an effective treatment in patients with pemphigus vulgaris and demonstrates a steroid-sparing effect. <i>British Journal of Dermatology</i> , 2020, 182, 1111-1119.	1.4	55
62	Cutaneous tests and interest of iobitridol in non-immediate hypersensitivity to contrast media: a case series of 43 patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e178-e180.	1.3	5
63	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	2.5	18
64	Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: french national audit of practices, literature review, and consensus agreement. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 259.	1.2	14
65	Iloprost: a potential alternative for skin graft-resistant hypertensive leg ulcer. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e726-e728.	1.3	2
66	Primary Cutaneous CD4+ Small/Medium T-Cell Lymphoproliferative Disorders. <i>American Journal of Surgical Pathology</i> , 2020, 44, 862-872.	2.1	36
67	Factors Associated With Short-term Relapse in Patients With Pemphigus Who Receive Rituximab as First-line Therapy. <i>JAMA Dermatology</i> , 2020, 156, 545.	2.0	40
68	Extensive cutaneous and muscular mucormycosis complicating insulin pump treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e486-e489.	1.3	0
69	Strong reactions to diltiazem patch tests: Plea for a low concentration. <i>Contact Dermatitis</i> , 2020, 83, 224-225.	0.8	4
70	HAVCR2 mutations are associated with severe hemophagocytic syndrome in subcutaneous panniculitis-like T-cell lymphoma. <i>Blood</i> , 2020, 135, 1058-1061.	0.6	29
71	Health-related quality of life and long-term related conditions in survivors of epidermal necrolysis: a study of 57 patients. <i>British Journal of Dermatology</i> , 2020, 182, e145.	1.4	1
72	Outcome and clinicophenotypical features of acute lymphoblastic leukemia/lymphoblastic lymphoma with cutaneous involvement: A multicenter case series. <i>Journal of the American Academy of Dermatology</i> , 2020, 83, 1166-1170.	0.6	6

#	ARTICLE	IF	CITATIONS
73	Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells.. Journal of Clinical Oncology, 2020, 38, e20040-e20040.	0.8	2
74	Adenovirus-induced Erythema Multiforme: Eye and Genital Mucosal Involvement is Specific, Whereas Oral and Cutaneous Involvement is Not. Acta Dermato-Venereologica, 2020, 100, adv00181.	0.6	3
75	Interventions for erythema multiforme: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 842-849.	1.3	20
76	Acute generalized exanthematous pustulosis and epidermal necrolysis differ in innate cytokine patterns. Clinical and Experimental Allergy, 2019, 49, 1258-1261.	1.4	4
77	Incidence of bloodstream infections and predictive value of qualitative and quantitative skin cultures of patients with overlap syndrome or toxic epidermal necrolysis: A retrospective observational cohort study of 98 cases. Journal of the American Academy of Dermatology, 2019, 81, 342-347.	0.6	11
78	Disabling ocular sequelae of epidermal necrolysis: risk factors during the acute phase and associated sequelae. British Journal of Dermatology, 2019, 181, 421-422.	1.4	9
79	Cutaneous lymphomas appearing during treatment with biologics: 44 cases from the French Study Group on Cutaneous Lymphomas and French Pharmacovigilance Database. British Journal of Dermatology, 2019, 181, 616-618.	1.4	15
80	Lookalike and soundalike drugs: a potential cause of cutaneous adverse reactions to drugs. British Journal of Dermatology, 2019, 181, 626-627.	1.4	2
81	Idiopathic Stevens-Johnson syndrome and toxic epidermal necrolysis: Prevalence and patients' characteristics. Journal of the American Academy of Dermatology, 2019, 80, 1453-1455.	0.6	14
82	Higher Frequency of Dipeptidyl Peptidase-4 Inhibitor Intake in Bullous Pemphigoid Patients than in the French General Population. Journal of Investigative Dermatology, 2019, 139, 835-841.	0.3	69
83	Response to Cutaneous eruptions associated with haematological malignancies: the need for a unifying nomenclature™. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e193-e193.	1.3	4
84	Valaciclovir: a culprit drug for drug reaction with eosinophilia and systemic symptoms not to be neglected. Three cases. British Journal of Dermatology, 2019, 180, 666-667.	1.4	6
85	Gastrointestinal involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis: a retrospective case series. British Journal of Dermatology, 2019, 180, 1234-1235.	1.4	10
86	Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: Proportion and determinants of underreporting to pharmacovigilance. Journal of Allergy and Clinical Immunology: in Practice, 2019, 7, 1344-1346.	2.0	0
87	Dark skin phototype is associated with more severe ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. British Journal of Dermatology, 2019, 181, 212-213.	1.4	7
88	Drug-induced linear immunoglobulin A bullous dermatosis: A French retrospective pharmacovigilance study of 69 cases. British Journal of Clinical Pharmacology, 2019, 85, 570-579.	1.1	41
89	Large International Validation of ABSIS and PDAI Pemphigus Severity Scores. Journal of Investigative Dermatology, 2019, 139, 31-37.	0.3	55
90	Treatment of mycosis fungoides and SÅ©zary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma. British Journal of Dermatology, 2019, 180, 423-424.	1.4	5

#	ARTICLE	IF	CITATIONS
91	Post-traumatic stress disorder in Stevens-Johnson syndrome and toxic epidermal necrolysis: prevalence and risk factors. A prospective study of 31 patients. <i>British Journal of Dermatology</i> , 2019, 180, 1206-1213.	1.4	29
92	Quoi de neuf en dermatologie clinique?. <i>Annales De Dermatologie Et De Venereologie</i> , 2019, 146, 12S1-12S10.	0.5	0
93	Epidermal necrolysis and autoimmune diseases: two more observations supporting the concept that "toxic" epidermal necrolysis can be "non-toxic". <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e360-e361.		7
94	Cyclosporine for Epidermal Necrolysis: Absence of Beneficial Effect in a Retrospective Cohort of 174 Patients Exposed/Unexposed and Propensity Score-Matched Analyses. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1293-1300.	0.3	41
95	Lenalidomide as an Alternative to Thalidomide for Treatment of Recurrent Erythema Multiforme. <i>JAMA Dermatology</i> , 2018, 154, 487.	2.0	8
96	T-cell papulosis associated with B-cell malignancy: a distinctive clinicopathologic entity. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1469-1475.	1.3	19
97	Stevens-Johnson Syndrome During Pregnancy. <i>JAMA Dermatology</i> , 2018, 154, 224.	2.0	3
98	Epidermal necrolysis French national diagnosis and care protocol (PNDS; protocole national de) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 46</i>	1.2	54
99	Clinical and histologic features of Mycoplasma pneumoniae-related erythema multiforme: A single-center series of 33 cases compared with 100 cases induced by other causes. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 110-117.	0.6	41
100	A Single-Arm Phase II Trial of Lenalidomide in Relapsing or Refractory Primary Cutaneous Large B-Cell Lymphoma, Leg Type. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1982-1989.	0.3	27
101	Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome due to ethambutol. <i>MÃ©decine Et Maladies Infectieuses</i> , 2018, 48, 302-305.	5.1	8
102	Lymphomatoid papulosis associated with chronic lymphocytic leukaemia/small lymphocytic lymphoma: three cases. <i>British Journal of Dermatology</i> , 2018, 178, e5-e6.	1.4	6
103	Severe sequelae of erythema multiforme: three cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e34-e36.	1.3	9
104	Treatment of prurigo with methotrexate: a multicentre retrospective study of 39 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 437-440.	1.3	30
105	A large epidemiological study of erythema multiforme in France, with emphasis on treatment choices. <i>British Journal of Dermatology</i> , 2018, 179, 1009-1011.	1.4	7
106	Primary cutaneous mucormycosis as a complication of erosive dermatitis: two cases. <i>European Journal of Dermatology</i> , 2018, 28, 227-229.	0.3	2
107	Association Between Severe Acute Contact Dermatitis Due to <i>Nigella sativa</i> Oil and Epidermal Apoptosis. <i>JAMA Dermatology</i> , 2018, 154, 1062.	2.0	22
108	Gliptin Accountability in Mucous Membrane Pemphigoid Induction in 24 Out of 313 Patients. <i>Frontiers in Immunology</i> , 2018, 9, 1030.	2.2	36

#	ARTICLE	IF	CITATIONS
109	Polysensitivity in delayed cutaneous adverse drug reactions to macrolides, clindamycin and pristinamycin: clinical history and patch testing. <i>British Journal of Dermatology</i> , 2018, 179, 978-979.	1.4	7
110	Urgences dermatologiques en réanimation : infections nosocomiales de la peau et des parties molles et toxidermies graves. <i>Medecine Intensive Reanimation</i> , 2018, 27, 461-474.	0.1	0
111	Republication de: Traitement des toxidermies graves. <i>Journal Europeen Des Urgences Et De Reanimation</i> , 2018, 30, 161-171.	0.1	0
112	Febrile ulceronecrotic Mucha Habermann disease mimicking aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma: a diagnostic challenge. <i>European Journal of Dermatology</i> , 2018, 28, 834-835.	0.3	7
113	Central nervous system involvement of primary cutaneous diffuse large B-cell lymphoma, leg type: 13 cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e498-e501.	1.3	11
114	Efficacy and Tolerance of Anti-Tumor Necrosis Factor ± Agents in Cutaneous Sarcoidosis. <i>JAMA Dermatology</i> , 2017, 153, 681.	2.0	46
115	First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial. <i>Lancet, The</i> , 2017, 389, 2031-2040.	6.3	438
116	Idiopathic linear IgA bullous dermatosis: prognostic factors based on a case series of 72 adults. <i>British Journal of Dermatology</i> , 2017, 177, 212-222.	1.4	42
117	The diagnosis is in the rings. <i>BMJ: British Medical Journal</i> , 2017, 359, j3817.	2.4	11
118	Self-diagnosed drug allergies: the belief of patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, e524-e526.	1.3	1
119	Immediate hypersensitivity reaction to pegylated liposomal doxorubicin: management and outcome in four patients. <i>European Journal of Dermatology</i> , 2017, 27, 271-274.	0.3	11
120	A polymorphous bullous dermatosis. <i>Lancet Oncology, The</i> , 2017, 18, e776.	5.1	1
121	Dermatitis herpetiformis and bone mineral density: analysis of a French cohort of 53 patients. <i>European Journal of Dermatology</i> , 2017, 27, 353-358.	0.3	5
122	Dermatological emergencies: evolution from 2008 to 2014 and perspectives. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 274-279.	1.3	15
123	Primary Cutaneous Follicle Center Lymphomas Expressing BCL2 Protein Frequently Harbor BCL2 Gene Break and May Present 1p36 Deletion. <i>American Journal of Surgical Pathology</i> , 2016, 40, 127-136.	2.1	31
124	Cutaneous Tumor of the Arm Revealing a Sporadic Burkitt Lymphoma. <i>Journal of the American Geriatrics Society</i> , 2016, 64, 1141-1142.	1.3	0
125	Epstein-Barr virus-associated B-cell lymphoproliferative disorder in a patient with Sjögren syndrome treated by methotrexate. <i>British Journal of Dermatology</i> , 2016, 175, 430-433.	1.4	4
126	Rituximab, a new treatment for difficult-to-treat chronic erythema multiforme major? Five cases. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1140-1143.	1.3	15

#	ARTICLE	IF	CITATIONS
127	Calculation of cutaneous values based on the Autoimmune Bullous Skin Disorder Intensity Score () Tj ETQq1 1 0.784314 rgBT /Overlock for defining moderate, significant and extensive types of pemphigus. British Journal of Dermatology, 2016, 175, 142-149.	1.4	68
128	Pemphigoid gestationis revealing a denial of pregnancy. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 1411-1413.	1.3	3
129	Frequency and Risk Factors for Associated Lymphomas in Patients With Lymphomatoid Papulosis. Oncologist, 2016, 21, 76-83.	1.9	42
130	Assessment of diagnostic criteria between primary cutaneous anaplastic large-cell lymphoma and CD30-rich transformed mycosis fungoides; a study of 66 cases. British Journal of Dermatology, 2015, 172, 1547-1554.	1.4	58
131	Folliculotropic T-cell infiltrates associated with B-cell chronic lymphocytic leukaemia or <sc>MALT</sc> lymphoma may reveal either true mycosis fungoides or pseudolymphomatous reaction: seven cases and review of the literature. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 77-85.	1.3	11
132	Primary cutaneous T-cell lymphoma presenting as mycosis fungoides with a T/null-cell phenotype: report of two cases. British Journal of Dermatology, 2015, 172, 1637-1641.	1.4	6
133	Frequency and prognostic value of cutaneous molecular residual disease in mycosis fungoides: a prospective multicentre trial of the Cutaneous Lymphoma French Study Group. British Journal of Dermatology, 2015, 173, 1015-1023.	1.4	11
134	First-line Treatment of Pemphigus Vulgaris With a Combination of Rituximab and High-Potency Topical Corticosteroids. JAMA Dermatology, 2015, 151, 200.	2.0	48
135	SÅ©zary syndrome without erythroderma. Journal of the American Academy of Dermatology, 2015, 72, 1003-1009.e1.	0.6	19
136	Atypical psoriasis. BMJ, The, 2015, 351, h5510.	3.0	1
137	Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. JAMA Dermatology, 2015, 151, 302.	2.0	31
138	Nodules on a sternotomy scar. Lancet Infectious Diseases, The, 2015, 15, 986.	4.6	2
139	Efficacy of Vinblastine in Primary Cutaneous Anaplastic Large Cell Lymphoma. JAMA Dermatology, 2015, 151, 1030.	2.0	8
140	Positive Direct Immunofluorescence Is of Better Value than ELISA-BP180 and ELISA-BP230 Values for the Prediction of Relapse after Treatment Cessation in Bullous Pemphigoid: A Retrospective Study of 97 Patients. Dermatology, 2015, 231, 50-55.	0.9	19
141	Stevens-Johnson syndrome and toxic epidermal necrolysis: follow-up of pulmonary function after remission. British Journal of Dermatology, 2015, 172, 400-405.	1.4	26
142	Primary cutaneous aggressive epidermotropic <sc>CD8</sc>+ T-cell lymphoma with <sc>KIR3DL2</sc> and <sc>NKP46</sc> expression in a human immunodeficiency virus carrier. Journal of Cutaneous Pathology, 2015, 42, 199-205.	0.7	10
143	Acute generalized exanthematous pustulosis: a retrospective audit of practice between 1994 and 2011 at a single centre. British Journal of Dermatology, 2015, 172, 1455-1457.	1.4	34
144	Linear immunoglobulin A disease and vancomycin: letter in reply. British Journal of Dermatology, 2014, 171, 1602-1604.	1.4	1

#	ARTICLE	IF	CITATIONS
145	Allogeneic stem cell transplantation for advanced cutaneous T-cell lymphomas: a study from the French Society of Bone Marrow Transplantation and French Study Group on Cutaneous Lymphomas. <i>Haematologica</i> , 2014, 99, 527-534.	1.7	73
146	Rituximab-related urticarial reaction overlying primary cutaneous follicle centre lymphoma: histological appearance and pathophysiological hypotheses. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2014, 28, 976-978.	1.3	10
147	Improvement of Survival in Patients With Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, in France. <i>JAMA Dermatology</i> , 2014, 150, 535.	2.0	80
148	Epidermolysis bullosa acquisita-like eruption with anticollagen VII autoantibodies induced by penicillamine in Wilson disease. <i>British Journal of Dermatology</i> , 2014, 171, 1574-1576.	1.4	7
149	Severe Cutaneous Adverse Reactions to Drugs: From Patients to the National Office for Compensation of Medical Accidents. <i>Dermatology</i> , 2014, 228, 338-343.	0.9	5
150	Dermatological emergencies: a comparative study of activity in 2000 and 2010. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 916-918.	1.3	26
151	Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients. <i>British Journal of Dermatology</i> , 2013, 169, 1223-1232.	1.4	121
152	Prognosis of generalized bullous fixed drug eruption: comparison with Stevens-Johnson syndrome and toxic epidermal necrolysis. <i>British Journal of Dermatology</i> , 2013, 168, 726-732.	1.4	100
153	IgG4-Related Skin Disease Successfully Treated by Thalidomide. <i>JAMA Dermatology</i> , 2013, 149, 742.	2.0	35
154	Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response. <i>Science Translational Medicine</i> , 2013, 5, 175ra30.	5.8	200
155	IgG4-Related Skin Disease—Reply. <i>JAMA Dermatology</i> , 2013, 149, 1440.	2.0	3
156	Linear IgA bullous dermatosis: comparison between the drug-induced and spontaneous forms. <i>British Journal of Dermatology</i> , 2013, 169, 1041-1048.	1.4	99
157	Suspected Viral Maculopapular Eruptions: An Audit of Practice. <i>Dermatology</i> , 2013, 227, 72-77.	0.9	2
158	HIV-Related CD8+ Cutaneous Pseudolymphoma: Efficacy of Methotrexate. <i>Dermatology</i> , 2013, 226, 15-18.	0.9	16
159	The Value of BP230 Enzyme-Linked Immunosorbent Assay in the Diagnosis and Immunological Follow-Up of Bullous Pemphigoid. <i>Dermatology</i> , 2012, 224, 154-159.	0.9	19
160	Dermatosurgery: Total Quality Management in a Dermatology Department. <i>Dermatology</i> , 2012, 225, 204-209.	0.9	2
161	Extensive telangiectases of the scalp: atypical presentation of primary cutaneous follicle centre lymphoma. <i>British Journal of Haematology</i> , 2012, 158, 297-297.	1.2	5
162	Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid: an open, multicentre, retrospective study. <i>British Journal of Dermatology</i> , 2011, 165, 1337-1343.	1.4	47

#	ARTICLE	IF	CITATIONS
163	Risk Factors for Bullous Pemphigoid in the Elderly: A Prospective Caseâ€“Control Study. <i>Journal of Investigative Dermatology</i> , 2011, 131, 637-643.	0.3	248
164	Management of Bullous Pemphigoid with Topical Steroids in the Clinical Practice of a Single Center: Outcome at 6 and 12 Months. <i>Dermatology</i> , 2011, 222, 176-179.	0.9	17
165	Bacteremia in Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis. <i>Medicine (United States)</i> , 2010, 89, 28-36.	0.4	80
166	Erythema multiforme associated with antiâ€“plakin antibodies: a multicentric retrospective case series. <i>Journal of the European Academy of Dermatology and Venereology</i> , 0, , .	1.3	3